jRCT2031200369进行中（未招募）不适用
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINYGastric04)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 490
- 主要终点
- Overall Survival
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Adults (according to local regulation) and able to provide informed consent for study participation.
- •Pathologically documented gastric and GEJ adenocarcinoma that has been previously treated in the metastatic setting (unresectable, locally advanced, or metastatic disease).
- •Progression on or after first-line therapy with a trastuzumab or approved trastuzumab biosimilar-containing regimen. Note: Prior adjuvant therapy with a trastuzumab-containing regimen can be counted as a line of therapy if the subject progressed on or within 6 months of completing adjuvant therapy.
- •Locally or centrally confirmed HER2-positive (IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH) as classified by ASCO-CAP on a tumor biopsy obtained after progression on or after a first-line trastuzumab or approved trastuzumab biosimilar-containing regimen.
- •Eastern Cooperative Oncology Group performance status of 0 or 1 at both Screening and within 3 days prior to randomization.
- •Adequate bone marrow, renal, and hepatic function within 14 days of randomization.
排除标准
- •Use of anticancer therapy after trastuzumab-containing treatment
- •Medical history of myocardial infarction (MI) within 6 months before randomization/enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV).
- •Has a QT interval corrected by Fridericia's formula (QTcF) prolongation to >470 msec (female subjects) or >450 msec (male subjects) based on average of the Screening triplicate12-lead ECG.
- •Has a pleural effusion, ascites, or pericardial effusion that requires drainage, peritoneal shunt, or cell-free and concentrated ascites reinfusion therapy (CART). Drainage and CART must be at least 2 weeks prior to Screening.
- •Has a history of (non-infectious) interstitial lung disease (ILD/pneumonitis) that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
- •Any autoimmune, connective tissue or inflammatory disorders (eg, rheumatoid arthritis, Sjogren syndrome, sarcoidosis, etc.) where there is documented (or a suspicion of) pulmonary involvement at the time of Screening.
- •Prior pneumonectomy.
- •Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- •Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated.
- •History of severe hypersensitivity reactions to either the T-DXd or inactive ingredients in T-DXd.
- •History of severe hypersensitivity reactions to other monoclonal antibodies or any components used in the ramucirumab drug product preparation
- •Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy such as peripheral neuropathy, Grade
- •Current uncontrolled infection requiring antibiotics, antivirals, or antifungals or an unexplained fever >38.0 C during Screening visits or on the first scheduled day of dosing (at the discretion of the Investigator, participants with tumor fever may be enrolled), which in the Investigator's opinion might compromise the participant's participation in the study or affect the study outcome
- •Clinically significant gastrointestinal disorder (eg, including hepatic disorders, bleeding, inflammation, occlusion, ileus, diarrhea Grade >1, jaundice, intestinal paralysis, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, or partial bowel obstruction) in the opinion of Investigator
- •Has history of receiving live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.
结局指标
主要结局
Overall Survival
Participants who were administered Trastuzumab Deruxtecan compared with Ramucirumab in Combination with Paclitaxel
次要结局
- Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)
- Percentage of Participants Who Have Treatment-emergent ADAs
研究者
相似试验
已完成
不适用
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCNon-Small Cell Lung CancerjRCT2071220096DAIICHI SANKYO Co.,Ltd.30
进行中（未招募）
不适用
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study - TRAIN studyHER2 positive breat cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-000987-18-NLetherlands Cancer Institute
已完成
不适用
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.HER2 positive gastric cancerJPRN-UMIN000005792Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences30
招募中
不适用
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerBreast CancerNCT06727227AstraZeneca138
已完成
2 期
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT04644237Daiichi Sankyo152